The latest phase 2 readout for Q32 Bio’s alopecia hopeful received a warm reception from investors, supporting the biotech’s case that the drug could offer a more durable alternative to JAK inhibitors.
The latest phase 2 readout for Q32 Bio’s alopecia hopeful received a warm reception from investors, supporting the biotech’s case that the drug could offer a more durable alternative to JAK inhibitors.
